<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2007-11-18" updated="2020-01-02">
  <drugbank-id primary="true">DB05528</drugbank-id>
  <name>Mipomersen</name>
  <description>Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications. It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported. Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program.</description>
  <cas-number>1000120-98-8</cas-number>
  <unii>9GJ8S4GU0M</unii>
  <average-mass>7177.11</average-mass>
  <monoisotopic-mass>7172.091682609</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3676</ref-id>
        <pubmed-id>17030687</pubmed-id>
        <citation>Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006 Oct 17;114(16):1729-35. Epub 2006 Oct 9.</citation>
      </article>
      <article>
        <ref-id>A3677</ref-id>
        <pubmed-id>23564617</pubmed-id>
        <citation>Hair P, Cameron F, McKeage K: Mipomersen sodium: first global approval. Drugs. 2013 Apr;73(5):487-93. doi: 10.1007/s40265-013-0042-2.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Used in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.</indication>
  <pharmacodynamics>Mipomersen sodium decreases the levels of apolipoprotein B (apo B), low density lipoprotein (LDL) non-high density lipoprotein-cholesterol, and total cholesterol.</pharmacodynamics>
  <mechanism-of-action>Mipomersen binds to the mRNA that codes for apoB-100. This binding leads to double-stranded RNA, which is degraded by RNase H and prevents translation of the mRNA to form the apo B-100 protein.</mechanism-of-action>
  <toxicity>The FDA label includes a black box warning of mipomersem induced hepatoxicity. Other less serious adverse effects include nausea, headache, fatigue, local injection site reactions, and flu-like symptoms.</toxicity>
  <metabolism>Mipomersem is metabolized by endonucleases. Once degraded into shorter oligonucleotides, it is metabolized further by exonucleases.&#13;
</metabolism>
  <absorption>The maximum mipomersen concentration is reached in about 3-4 hours after subcutaneous injection. Additionally the bioavailability of mipomersn is dose-dependant and ranges from 54%-78%.</absorption>
  <half-life>Mipomersem has a very long half life of 1-2 months.</half-life>
  <protein-binding>Plasma protein binding for mipomersen is greater than or equal to 90%.</protein-binding>
  <route-of-elimination>24 hours after mipomersem administration, less than 4% of mipomersem and/or it's metabolites were excreted in the urine.</route-of-elimination>
  <volume-of-distribution>The volume of distribution for mipomersen was not quantified.</volume-of-distribution>
  <clearance>Clearance of mipomersem was not quantified.</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phosphorothioate polynucleotides. These are polynucleotides in which one of the non-bridging oxygens in each phosphodiester linkage has been replaced by sulfur.</description>
    <direct-parent>Phosphorothioate polynucleotides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic Polymers</superclass>
    <class>Phosphorothioate polynucleotides</class>
    <subclass/>
    <alternative-parent>6-aminopurines</alternative-parent>
    <alternative-parent>Aminopyrimidines and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Dialkyl ethers</alternative-parent>
    <alternative-parent>Glycosylamines</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydropyrimidines</alternative-parent>
    <alternative-parent>Hydroxypyrimidines</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <alternative-parent>Polysaccharides</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Pyrimidine nucleosides</alternative-parent>
    <alternative-parent>Pyrimidones</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Tetrahydrofurans</alternative-parent>
    <alternative-parent>Thiophosphate diesters</alternative-parent>
    <substituent>6-aminopurine</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Amine</substituent>
    <substituent>Aminopyrimidine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Dialkyl ether</substituent>
    <substituent>Ether</substituent>
    <substituent>Glycosyl compound</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Hydropyrimidine</substituent>
    <substituent>Hydroxypyrimidine</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Imidazopyrimidine</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>N-glycosyl compound</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic thiophosphoric acid or derivatives</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Phosphorothioate polynucleotide</substituent>
    <substituent>Polysaccharide</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Purine</substituent>
    <substituent>Pyrimidine</substituent>
    <substituent>Pyrimidine nucleoside</substituent>
    <substituent>Pyrimidone</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tetrahydrofuran</substituent>
    <substituent>Thiophosphate diester</substituent>
    <substituent>Thiophosphoric acid ester</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000120</drugbank-id>
      <name>Mipomersen sodium</name>
      <unii>18EAY4870E</unii>
      <cas-number>629167-92-6</cas-number>
      <inchikey>XLTMUFRACYRYJG-UHFFFAOYSA-A</inchikey>
      <average-mass>7594.76</average-mass>
      <monoisotopic-mass>7589.74862332</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Mipomersen</synonym>
  </synonyms>
  <products>
    <product>
      <name>Kynamro</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-29</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA203568</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kynamro</name>
      <labeller>Kastle Therapeutics, Llc</labeller>
      <ndc-id/>
      <ndc-product-code>70688-0502</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA203568</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kynamro</name>
      <labeller>Genzyme Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>58468-0190</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-29</started-marketing-on>
      <ended-marketing-on>2013-01-29</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>200 mg/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA203568</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kynamro</name>
      <ingredients>Mipomersen</ingredients>
    </mixture>
    <mixture>
      <name>Kynamro</name>
      <ingredients>Mipomersen</ingredients>
    </mixture>
    <mixture>
      <name>Kynamro</name>
      <ingredients>Mipomersen</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anticholesteremic Agents</category>
      <mesh-id>D000924</mesh-id>
    </category>
    <category>
      <category>Antisense Elements (Genetics)</category>
      <mesh-id>D016375</mesh-id>
    </category>
    <category>
      <category>Apolipoprotein B-100 Synthesis Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Compounds used in a research, industrial, or household setting</category>
      <mesh-id>D020313</mesh-id>
    </category>
    <category>
      <category>Decreased Protein Synthesis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Diagnostic Uses of Chemicals</category>
      <mesh-id>D064907</mesh-id>
    </category>
    <category>
      <category>DNA</category>
      <mesh-id>D004247</mesh-id>
    </category>
    <category>
      <category>DNA, Antisense</category>
      <mesh-id>D016373</mesh-id>
    </category>
    <category>
      <category>Glycosides</category>
      <mesh-id>D006027</mesh-id>
    </category>
    <category>
      <category>Hepatotoxic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hypolipidemic Agents</category>
      <mesh-id>D000960</mesh-id>
    </category>
    <category>
      <category>Laboratory Chemicals</category>
      <mesh-id>D019995</mesh-id>
    </category>
    <category>
      <category>Lipid Modifying Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipid Modifying Agents, Plain</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipid Regulating Agents</category>
      <mesh-id>D057847</mesh-id>
    </category>
    <category>
      <category>Molecular Probes</category>
      <mesh-id>D015335</mesh-id>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>Nucleic Acid Probes</category>
      <mesh-id>D015341</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids</category>
      <mesh-id>D009696</mesh-id>
    </category>
    <category>
      <category>Nucleic Acids, Nucleotides, and Nucleosides</category>
      <mesh-id>D009706</mesh-id>
    </category>
    <category>
      <category>Nucleotides</category>
      <mesh-id>D009711</mesh-id>
    </category>
    <category>
      <category>Oligodeoxyribonucleotides, Antisense</category>
      <mesh-id>D020319</mesh-id>
    </category>
    <category>
      <category>Oligonucleotides</category>
      <mesh-id>D009841</mesh-id>
    </category>
    <category>
      <category>Oligonucleotides, Antisense</category>
      <mesh-id>D016376</mesh-id>
    </category>
    <category>
      <category>Polynucleotides</category>
      <mesh-id>D011119</mesh-id>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>200 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="C10AX11">
      <level code="C10AX">Other lipid modifying agents</level>
      <level code="C10A">LIPID MODIFYING AGENTS, PLAIN</level>
      <level code="C10">LIPID MODIFYING AGENTS</level>
      <level code="C">CARDIOVASCULAR SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB05528.pdf?1371087391</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB05528.pdf?1371087391</msds>
  <patents>
    <patent>
      <number>7407943</number>
      <country>United States</country>
      <approved>2008-08-05</approved>
      <expires>2021-08-01</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7015315</number>
      <country>United States</country>
      <approved>2006-03-21</approved>
      <expires>2023-03-21</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7511131</number>
      <country>United States</country>
      <approved>2009-03-31</approved>
      <expires>2025-12-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6451991</number>
      <country>United States</country>
      <approved>2002-09-17</approved>
      <expires>2017-02-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6166197</number>
      <country>United States</country>
      <approved>2000-12-26</approved>
      <expires>2017-12-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7101993</number>
      <country>United States</country>
      <approved>2006-09-05</approved>
      <expires>2023-09-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Limit alcohol to a daily maximum of 1 drink (or equivalent) while using mipomersen sodium.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>Doxycycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00256</drugbank-id>
      <name>Lymecycline</name>
      <description>Lymecycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00453</drugbank-id>
      <name>Clomocycline</name>
      <description>Clomocycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00560</drugbank-id>
      <name>Tigecycline</name>
      <description>Tigecycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00595</drugbank-id>
      <name>Oxytetracycline</name>
      <description>Oxytetracycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00618</drugbank-id>
      <name>Demeclocycline</name>
      <description>Demeclocycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>Tetracycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00931</drugbank-id>
      <name>Metacycline</name>
      <description>Metacycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Minocycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01301</drugbank-id>
      <name>Rolitetracycline</name>
      <description>Rolitetracycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>Sarecycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12329</drugbank-id>
      <name>Eravacycline</name>
      <description>Eravacycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>Omadacycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13092</drugbank-id>
      <name>Meclocycline</name>
      <description>Meclocycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13264</drugbank-id>
      <name>Penimepicycline</name>
      <description>Penimepicycline may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>Acetaminophen may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>Propacetamol may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>Mipomersen may increase the hepatotoxic activities of Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>Tamoxifen may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Isotretinoin may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>Amiodarone may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>Lomitapide may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Ethanol may increase the hepatotoxic activities of Mipomersen.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>13.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>({2-[({[(2-{[({[2-({[({2-[({[(2-{[({[2-({[({2-[({[(2-{[({[5-(6-amino-9H-purin-9-yl)-2-({[hydroxy({[2-({[hydroxy({[2-({[hydroxy({[2-({[hydroxy({[2-({[hydroxy({[5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)oxolan-3-yl]oxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]methyl}-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-3-yl)oxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)methyl]-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-3-yl}oxy)(hydroxy)sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)oxolan-3-yl]oxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]methyl}-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-3-yl)oxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)methyl]-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)oxolan-3-yl}oxy)(hydroxy)sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)oxolan-3-yl]oxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]methyl}-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-3-yl)oxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)methyl]-5-(4-hydroxy-5-methyl-2-oxo-1,2-dihydropyrimidin-1-yl)oxolan-3-yl}oxy)({[3-({[(3-{[({3-[({[5-(6-amino-9H-purin-9-yl)-3-({hydroxy[(3-{[hydroxy({[3-hydroxy-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy})sulfanylidene-λ⁵-phosphanyl]oxy}-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-2-yl)methoxy]sulfanylidene-λ⁵-phosphanyl}oxy)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-λ⁵-phosphanyl]oxy}-5-(6-hydroxy-2-imino-3,9-dihydro-2H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)-5-(2-hydroxy-4-imino-5-methyl-1,4-dihydropyrimidin-1-yl)oxolan-2-yl]methoxy})sulfanylidenephosphinous acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>{2-[({[(2-{[({[2-({[({2-[({[(2-{[({[2-({[({2-[({[(2-{[({[5-(6-aminopurin-9-yl)-2-({[hydroxy({[2-({[hydroxy({[2-({[hydroxy({[2-({[hydroxy({[2-({[hydroxy({[5-(6-hydroxy-2-imino-3H-purin-9-yl)-2-(hydroxymethyl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-3-yl]oxy})sulfanylidene-λ⁵-phosphanyl]oxy}methyl)oxolan-3-yl]oxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]methyl}-5-(6-hydroxy-2-imino-3H-purin-9-yl)oxolan-3-yl)oxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)methyl]-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)oxolan-3-yl}oxy)(hydroxy)sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)oxolan-3-yl]oxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]methyl}-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)oxolan-3-yl)oxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)methyl]-5-(6-hydroxy-2-imino-3H-purin-9-yl)oxolan-3-yl}oxy)(hydroxy)sulfanylidene-λ⁵-phosphanyl]oxy}methyl)-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)oxolan-3-yl]oxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]methyl}-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)oxolan-3-yl)oxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)methyl]-5-(4-hydroxy-5-methyl-2-oxopyrimidin-1-yl)oxolan-3-yl}oxy([3-({[(3-{[({3-[({[5-(6-aminopurin-9-yl)-3-({hydroxy[(3-{[hydroxy({[3-hydroxy-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy})sulfanylidene-λ⁵-phosphanyl]oxy}-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-2-yl)methoxy]sulfanylidene-λ⁵-phosphanyl}oxy)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy}(hydroxy)sulfanylidene-λ⁵-phosphanyl)oxy]-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)-4-(2-methoxyethoxy)oxolan-2-yl}methoxy)(hydroxy)sulfanylidene-λ⁵-phosphanyl]oxy}-5-(6-hydroxy-2-imino-3H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl)methoxy](hydroxy)sulfanylidene-λ⁵-phosphanyl}oxy)-5-(2-hydroxy-4-imino-5-methylpyrimidin-1-yl)oxolan-2-yl]methoxy)sulfanylidenephosphinous acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>7177.11</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>7172.091682609</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H]C1(CC([H])(OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(CC2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C3NC(=N)N=C4O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=NC4=C(N)N=CN=C34)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])OP(O)(=S)OCC2([H])OC([H])(N3C=C(C)C(=N)N=C3O)C([H])(OCCOC)C2([H])O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=NC3=C2NC(=N)N=C3O)N2C=C(C)C(O)=NC2=O)N2C=C(C)C(=N)N=C2O)N2C=C(C)C(O)=NC2=O)C([H])(COP(O)(=S)OC2([H])CC([H])(OC2([H])COP(O)(=S)OC2([H])C([H])(COP(O)(=S)OC3([H])C([H])(COP(O)(=S)OC4([H])C([H])(COP(O)(=S)OC5([H])C([H])(COP(O)(=S)OC6([H])C([H])(CO)OC([H])(N7C=NC8=C7NC(=N)N=C8O)C6([H])OCCOC)OC([H])(N6C=C(C)C(=N)N=C6O)C5([H])OCCOC)OC([H])(N5C=C(C)C(=N)N=C5O)C4([H])OCCOC)OC([H])(N4C=C(C)C(O)=NC4=O)C3([H])OCCOC)OC([H])(N3C=C(C)C(=N)N=C3O)C2([H])OCCOC)N2C=NC3=C(N)N=CN=C23)O1)N1C=NC2=C1NC(=N)N=C2O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C230H324N67O122P19S19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C230H324N67O122P19S19/c1-97-55-278(217(309)256-177(97)231)141-45-111(122(381-141)70-362-422(325,441)404-116-50-146(283-66-108(12)196(302)275-228(283)320)387-128(116)76-368-427(330,446)410-120-54-150(294-93-253-154-191(294)266-214(243)270-200(154)306)390-130(120)78-370-428(331,447)408-118-52-148(292-91-250-151-186(240)246-89-248-188(151)292)388-131(118)79-371-430(333,449)412-159-134(394-204(169(159)354-37-27-344-17)286-59-101(5)181(235)260-221(286)313)83-375-435(338,454)417-164-138(398-209(174(164)359-42-32-349-22)291-68-110(14)198(304)277-230(291)322)87-377-434(337,453)415-162-136(396-207(172(162)357-40-30-347-20)289-62-104(8)184(238)263-224(289)316)85-376-433(336,452)414-161-133(393-206(171(161)356-39-29-346-19)288-61-103(7)183(237)262-223(288)315)82-374-432(335,451)411-158-121(69-298)391-211(168(158)353-36-26-343-16)296-95-254-155-192(296)267-215(244)271-201(155)307)401-420(323,439)365-74-127-117(51-147(386-127)284-67-109(13)197(303)276-229(284)321)406-425(328,444)369-77-129-119(53-149(389-129)293-92-252-153-190(293)265-213(242)269-199(153)305)409-426(329,445)367-71-123-112(46-142(382-123)279-56-98(2)178(232)257-218(279)310)402-421(324,440)364-73-125-115(49-145(384-125)282-65-107(11)195(301)274-227(282)319)405-424(327,443)366-75-126-114(48-144(385-126)281-64-106(10)194(300)273-226(281)318)403-423(326,442)363-72-124-113(47-143(383-124)280-57-99(3)179(233)258-219(280)311)407-429(332,448)373-81-139-166(176(361-44-34-351-24)212(400-139)297-96-255-156-193(297)268-216(245)272-202(156)308)419-438(341,457)379-86-137-163(173(358-41-31-348-21)208(397-137)290-63-105(9)185(239)264-225(290)317)416-436(339,455)380-88-140-165(175(360-43-33-350-23)210(399-140)295-94-251-152-187(241)247-90-249-189(152)295)418-437(340,456)378-84-135-160(170(355-38-28-345-18)205(395-135)287-60-102(6)182(236)261-222(287)314)413-431(334,450)372-80-132-157(299)167(352-35-25-342-15)203(392-132)285-58-100(4)180(234)259-220(285)312/h55-68,89-96,111-150,157-176,203-212,298-299H,25-54,69-88H2,1-24H3,(H,323,439)(H,324,440)(H,325,441)(H,326,442)(H,327,443)(H,328,444)(H,329,445)(H,330,446)(H,331,447)(H,332,448)(H,333,449)(H,334,450)(H,335,451)(H,336,452)(H,337,453)(H,338,454)(H,339,455)(H,340,456)(H,341,457)(H2,231,256,309)(H2,232,257,310)(H2,233,258,311)(H2,234,259,312)(H2,235,260,313)(H2,236,261,314)(H2,237,262,315)(H2,238,263,316)(H2,239,264,317)(H2,240,246,248)(H2,241,247,249)(H,273,300,318)(H,274,301,319)(H,275,302,320)(H,276,303,321)(H,277,304,322)(H3,242,265,269,305)(H3,243,266,270,306)(H3,244,267,271,307)(H3,245,268,272,308)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XLTMQWVJFPYGMC-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>2430.79</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>1775.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>672.05</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>156</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>140</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>58</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.06</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>131704297</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827735</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D08946</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Mipomersen</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL502097</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/kynamro-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/mtm/mipomersen.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004845</id>
      <name>mRNA of ApoB-100</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>